ABSTRACT
Background During this pandemic, many studies have been published on the virology, diagnosis, prevention, and control of the novel coronavirus. However, fewer studies are currently available on the quantitative future epidemiological impacts. Therefore, the purpose of this study is to forecast the COVID-19 morbidities and associated-mortalities among the top 20 countries with the highest number of confirmed COVID-19 cases globally prior to vaccination intervention.
Method We conducted a secondary data analysis of the prospective geographic distribution of COVID-19 cases data worldwide as of 10 April 2020. The historical data was forecasted using Exponential-Smoothing to detect seasonality patterns and confidence intervals surrounding each predicted value in which 95 percent of the future points are expected to fall based on the forecast.
Results The total mean forecasted cases and deaths were 99,823 and 8,801. Interestingly, the US has the highest forecasted cases, deaths, and percentage cases-deaths ratio of 45,338, 2 358, and 5.20% respectively. China has the lowest cases, deaths, and percentage cases-deaths ratio −267, −2, and 0.75% respectively. In addition, France has the highest forecasted percentage cases-deaths ratio of 26.40% with forecasted cases, and deaths of 6,246, and 1,649 respectively.
Conclusion Our study revealed the possibility of higher COVID-19 morbidities and associated-mortalities worldwide.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding for this project
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
European Centre for Disease Prevention and Control
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact Information: Amusatoladele{at}gmail.com; Saheed.amusat{at}student.uj.edu.pl; +2348165626654
Data Availability
The data is openly accessible via European Centre for Disease Prevention and Control
